Advertisement
Canada markets open in 5 hours 47 minutes

  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CAD/USD

    0.7327
    +0.0004 (+0.06%)
     

  • CRUDE OIL

    84.03
    +0.46 (+0.55%)
     

  • Bitcoin CAD

    87,786.35
    +479.99 (+0.55%)
     

  • CMC Crypto 200

    1,390.72
    -5.82 (-0.42%)
     

  • GOLD FUTURES

    2,355.30
    +12.80 (+0.55%)
     

  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • NASDAQ futures

    17,750.00
    +182.50 (+1.04%)
     

  • VOLATILITY

    15.54
    +0.17 (+1.11%)
     

  • FTSE

    8,122.65
    +43.79 (+0.54%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6826
    +0.0005 (+0.07%)
     

Arena (ARNA) Completes Enrolment in Etrasimod Phase II Study

Zacks Equity Research
Updated

Arena Pharmaceuticals, Inc. ARNA announced that it has completed full enrollment with 157 patients in a phase II study evaluating its pipeline candidate etrasimod in ulcerative colitis (UC). Etrasimod (APD334) is an orally available next-generation sphingosine 1-phosphate (S1P) receptor modulator.

The primary endpoint of the study is the improvement in UC symptoms as measured by Mayo Clinic Score at 12 week compared with placebo. Top-line results are expected to be available in the first quarter of 2018.

Meanwhile, Arena continues to progress with its pipeline that targets different therapeutic areas.These include ralinepag (pulmonary arterial hypertension), and APD371 (pain and fibrotic diseases).The company reported positive results from a phase II study on ralinepag in July and is preparing to initiate a phase III study after discussions with the FDA

Arena’s shares have outperformed the industry so far this year. While shares of the company have soared 88.4%, the industry has registered an increase of 2.3%.

ADVERTISEMENT

 

 

Several other companies are also evaluating some candidates for UC. Some of them include Pfizer PFE, which is conducting studies to expand the label of its rheumatoid arthritis drug  Xeljanz to include the UC indication. Another company, AbbVie Inc. ABBV is also looking to get its flagship product Humira approved for UC.  The company has another candidate upadacitinib/ABT-494 which is being evaluated for UC.

Zacks Rank & Stock to Consider

Arena carries a Zacks Rank #3 (Hold). Another better-ranked health care stocks in the same space is Ligand Pharmaceuticals Incorporated LGND sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Ligand’s earnings per share estimates have moved up $3.68 to $3.70 for 2018 over the last 60 days. The company pulled off positive earnings surprises in two of the trailing four quarters, with an average beat of 8.22%. The share price of the company has increased 37.6% year to date.

Will You Make a Fortune on the Shift to Electric Cars?

Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.

With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.

It's not the one you think.

See This Ticker Free >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Pfizer, Inc. (PFE) : Free Stock Analysis Report
 
AbbVie Inc. (ABBV) : Free Stock Analysis Report
 
Arena Pharmaceuticals, Inc. (ARNA) : Free Stock Analysis Report
 
Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research